Union européenne - maltais - EMA (European Medicines Agency)

dopharma research b.v. - meloxicam - oxicams - pigs; calves - cattlefor-użu fil-infezzjoni respiratorja akuta b'terapija antibijotika xierqa biex jitnaqqsu s-sinjali kliniċi fl-ifrat. għall-użu fid-dijarea flimkien ma 'terapija mill-ġdid ta' reidratazzjoni orali biex jitnaqqsu s-sinjali kliniċi f'għoġġiela ta 'aktar minn ġimgħa ta' età u baqar żgħar li ma jreddgħux. għal terapija aġġuntiva fit-trattament ta 'mastite akuta, flimkien ma' terapija antibijotika. pigsfor-użu fl-noninfectious disturbi lokomotorji biex jitnaqqsu s-sintomi ta'zappip u ta'infjammazzjoni. għall-eżenzjoni ta 'uġigħ wara l-operazzjoni assoċjat ma' kirurġija minuri tat-tessut artab bħal kastrazzjoni. għal terapija aġġuntiva fit-trattament ta 'settiċemija puerperali u toxaemia (sindrome mastite-metritis-agalactia) b'terapija antibijotika xierqa. horsesfor-użu sabiex tittaffa l-infjammazzjoni u serħan mill-uġigħ akut kif ukoll kroniku disturbi muskolu-skeletrali. għall-eżenzjoni ta 'uġigħ assoċjat ma' kolika ekwina.

Union européenne - maltais - EMA (European Medicines Agency)

zoetis belgium sa - meloxicam - anti-inflammatory and anti-rheumatic products, non-steroids - horses; pigs; cattle - cattlefor-użu fil-infezzjoni respiratorja akuta b'terapija antibijotika xierqa biex jitnaqqsu s-sinjali kliniċi. għal użu fid-dijarea flimkien ma 'terapija mill-ġdid ta' idratazzjoni mill-ħalq biex jitnaqqsu s-sinjali kliniċi f'għoġġiela ta 'aktar minn ġimgħa ta' età u baqar żgħar li ma jreddgħux. għal terapija aġġuntiva fit-trattament ta 'mastite akuta, flimkien ma' terapija antibijotika. għall-eżenzjoni ta 'uġigħ ta' wara l-operazzjoni wara t-tqaxxir fl-għoġġiela. pigsfor l-tnaqqis tas-sintomi ta'zappip u ta'infjammazzjoni fid-disturbi lokomotorji mhux infettivi u għal terapija addizzjonali fit-trattament ta 'settiċemija puwerperali u toxaemia (mastite-metrite-agalaktja) ma' terapija antibijotika adattata. horsesfor-użu sabiex tittaffa l-infjammazzjoni u serħan mill-uġigħ akut kif ukoll kroniku disturbi muskolu-skeletrali. għall-eżenzjoni ta 'uġigħ assoċjat ma' kolika ekwina.

Union européenne - maltais - EMA (European Medicines Agency)

inceptua ab - ocriplasmin - mard tar-retina - oftalmoloġiċi - jetrea huwa indikat fl-adulti għat-trattament ta 'traction vitreomacular (vmt), inkluż meta assoċjat ma' toqba makulari ta 'dijametru ta' 400 mikron jew anqas.

Union européenne - maltais - EMA (European Medicines Agency)

ucb pharma s.a.   - bimekizumab - psorajiżi - immunosoppressanti - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.

Union européenne - maltais - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - adalimumab - hidradenitis suppurativa; arthritis, psoriatic; psoriasis; crohn disease; arthritis, juvenile rheumatoid; uveitis; arthritis, rheumatoid; colitis, ulcerative; spondylitis, ankylosing - immunosoppressanti - jekk jogħġbok irreferi għas-sezzjoni 4. 1 tas-sommarju tal-karatteristiċi tal-prodott fid-dokument ta 'informazzjoni tal-prodott.

Union européenne - maltais - EMA (European Medicines Agency)

upjohn eesv - pregabalin - anxiety disorders; epilepsy - anti-epilettiċi, - newropatiku painpregabalin pfizer huwa indikat għat-trattament tal-uġigħ nevrotiku periferali u ċentrali f'persuni adulti. epilepsypregabalin pfizer huwa indikat bħala terapija aġġuntiva f'persuni adulti b'aċċessjonijiet parzjali bi jew mingħajr ġeneralizzazzjoni sekondarja. ta'ansjetà ġeneralizzata disorderpregabalin pfizer huwa indikat għall-kura ta 'disturb ta' ansjetà Ġeneralizzata (gad-generalised anxiety disorder) f'persuni adulti.

Union européenne - maltais - EMA (European Medicines Agency)

alexion europe sas - ravulizumab - emoglobinurja, paroxysmal - immunosuppressanti selettivi - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Union européenne - maltais - EMA (European Medicines Agency)

accord healthcare s.l.u. - filgrastim - newtropenja - immunostimulanti, - accofil huwa indikat għat-tnaqqis fid-dewmien ta 'newtropenja u l-inċidenza ta' newtropenja bid-deni f'pazjenti kkurati b'kimoterapija ċitotossika stabbilita għal malinn (bl-eċċezzjoni ta 'lewkimja majelojde kronika u sindromi majelodisplastiċi) u għat-tnaqqis fid-dewmien ta' newtropenja f'pazjenti li jkollhom terapija majeloablattiva segwita minn trapjant tal-mudullun li huma kkunsidrati li jkunu f'riskju akbar fit-tul ta ' newtropenja severa. is-sigurtà u l-effikaċja ta 'accofil huma simili fl-adulti u fit-tfal li qed jirċievu kimoterapija ċitotossika. accofil is indicated for the mobilisation of peripheral blood progenitor cells (pbpcs). f'pazjenti, tfal jew adulti b'severa konġenitali, ċiklika, jew newtropenja idjopatika bl-għadd assolut ta 'newtrofili (anc) ta' ≤ 0. 5 x 109 / l, u storja ta 'infezzjonijiet severi jew rikorrenti, l-amministrazzjoni fit-tul ta' accofil hija indikata biex iżżid l-għadd ta 'newtrofili u biex tnaqqas l-inċidenza u t-tul ta' avvenimenti relatati mal-infezzjonijiet. accofil is indicated for the treatment of persistent neutropenia (anc less than or equal to 1. 0 x 109 / l) f'pazjenti b'infezzjoni avvanzata ta 'l-hiv, sabiex jitnaqqas ir-riskju ta' infezzjonijiet batteriċi meta għażliet oħra biex tiġi amministrata n-newtropenija mhumiex xierqa.

Union européenne - maltais - EMA (European Medicines Agency)

sanofi b.v. - thyrotropin alfa - neoplażmi tat-tirojde - - lobu pitwitarju anterjuri-ormoni u analogi, pitwitarja u l-assi ipotalamika-ormoni u analogi - thyrogen is indicated for use with serum thyroglobulin (tg) testing with or without radioiodine imaging for the detection of thyroid remnants and well-differentiated thyroid cancer in post thyroidectomy patients maintained on hormone suppression therapy (thst). low risk patients with well-differentiated thyroid carcinoma who have undetectable serum tg levels on thst and no rh (recombinant human) tsh-stimulated increase of tg levels may be followed-up by assaying rh tsh-stimulated tg levels. thyrogen is indicated for pre-therapeutic stimulation in combination with a range of 30 mci (1. 1 gbq) to 100 mci (3. 7 gbq) radioiodine for ablation of thyroid tissue remnants in patients who have undergone a near-total or total thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of distant metastatic thyroid cancer (see section 4.

Union européenne - maltais - EMA (European Medicines Agency)

zentiva k.s. - pregabalin - anxiety disorders; neuralgia; epilepsy - anti-epilettiċi, - newropatiku painpregabalin zentiva k. hija indikata għat-trattament ta 'uġigħ newropatiku periferali u ċentrali fl-adulti. epilepsypregabalin zentiva k. huwa indikat bħala terapija aġġuntiva f'persuni adulti b'aċċessjonijiet parzjali bi jew mingħajr ġeneralizzazzjoni sekondarja. ta'ansjetà ġeneralizzata disorderpregabalin zentiva k. huwa indikat għall-kura ta 'disturb ta' ansjetà ġeneralizzata (gad-generalised anxiety disorder) f'persuni adulti.